Picture loading failed.

Anti-FOLR1 therapeutic antibody (Pre-made Mirvetuximab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Description. Mirvetuximab Soravtansine is an immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-349-1mg 1mg Inquiry
GMP-Bios-ab-349-10mg 10mg Inquiry
GMP-Bios-ab-349-100mg 100mg Inquiry
GMP-Bios-ab-349-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-FOLR1 therapeutic antibody (Pre-made Mirvetuximab biosimilar,Whole mAb ADC)
INN Name Mirvetuximab
FormatWhole mAb ADC
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesImmunoGen;National Comprehensive Cancer Network
Conditions Approvedna
Conditions ActiveFallopian tube cancer;Ovarian cancer;Peritoneal cancer;Breast cancer;Endometrial cancer
Conditions DiscontinuedSolid tumours
Development Techna